Dermata Therapeutics, Inc. (DRMA)
Largest Insider Buys in Sector
DRMA Stock Price History Chart
DRMA Stock Performance
About Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that …
Insider Activity of Dermata Therapeutics, Inc.
Over the last 12 months, insiders at Dermata Therapeutics, Inc. have bought $0 and sold $0 worth of Dermata Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Dermata Therapeutics, Inc. have bought $1.05M and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 152,857 shares for transaction amount of $1.05M was made by PROEHL GERALD T (President, CEO and Chairman) on 2021‑08‑16.
List of Insider Buy and Sell Transactions, Dermata Therapeutics, Inc.
| 2021-08-16 | President, CEO and Chairman | 152,857 0.2495% | $6.87 | $1.05M | -74.91% |
Insider Historical Profitability
| PROEHL GERALD T | President, CEO and Chairman | 152857 10.1216% | $1.55 | 1 | 0 | <0.0001% |